Pediatric Sinonasal Rhabdomyosarcoma: Clinical Characteristics and Surgical Role
Pediatric Sinonasal Rhabdomyosarcoma: Clinical Characteristics and Surgical Role
Download Citation in txt
Download Citation in bib
Download Citation in ris
Author Info
Abdullah Alshakhs Ahoud Almuneef Ali Al Momen Aziza A Alzubaidi Mohammed A. Alfalah Saad M. Alshammari Saad S Alotaibi
Corresponding Author
Ali Al MomenConsultant Rhinology & Skull Base Surgery, King Fahad Specialist Hospital, Kingdom of Saudi Arabia
A B S T R A C T
Introduction: Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma. It represents 5-8% of pediatric tumors. Head and neck is considered the most common site of RMS origin (40%). Parameningeal, orbital and non parameningeal RMS approximately represent 50%, 25% and 25% respectively. Histopathological evaluation demonstrates small round cells with high cytological variability which stain positive with desmin, myogenin and MyoD1. The mainstay treatment of RMS depends on chemotherapy and radiation therapy with a limited role of surgery. Method: A retrospective chart review for pediatric sinonasal rhabdomyosarcoma diagnosed and managed at King Fahad Specialist Hospital, Dammam, Saudi Arabia, and a literature review of pediatric sinonasal rhabdomyosarcoma was conducted. Results: A total of four cases were identified for the period (2011-2017), and a thorough review of their medical records and radiological imaging were done. Conclusion: Pediatric sinonasal rhabdomyosarcoma may initially present with symptoms mimicking rhinosinusitis. Biopsy and histological evaluation are the most essential steps to exclude malignancy. Intergroup Rhabdomyosarcoma Studies (IRS) established a staging system based on tumor extension and resectability. The role of surgery in RMS may be limited for obtaining biopsies for diagnosis and for palliative purposes. Popular antineoplastic agents used to treat RMS include vincristine, cyclophosphamide, actinomycin D, and adriamycin. Chemotherapy with alkylating agents has achieved a relapsed free survival 90% for nonparameningeal tumors and 65% for parameningeal tumors.
Article Info
Article Type
Case StudyPublication history
Received: Mon 02, Mar 2020Accepted: Wed 18, Mar 2020
Published: Fri 20, Mar 2020
Copyright
© 2023 Ali Al Momen . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.DOI: 10.31487/j.IJSCR.2020.01.08